Q-omics provides the consensus-scored ZNF101 profile across patient tissues and cancer cell-line models. ZNF101 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF101 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZNF101 RNA expression shows 20,697 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where ZNF101 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF101 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF101 survival associations across molecular data types. ZNF101 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF101 RNA expression–survival associations across cancer types. High ZNF101 expression shows unfavorable associations in KICH and LGG, but favorable associations in HNSC, LUAD, STAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF101 RNA expression.
This table summarizes ZNF101 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF101. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF101 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, UCEC, BLCA and STAD. The THCA box plot shows higher ZNF101 RNA expression in normal versus tumor tissue (log2 FC = −0.727, t-test p < 0.001).
This table shows molecular features associated with ZNF101 in patient tissues and cancer cell lines. In patient samples, ZNF101 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF101 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
